Perrigo’s 2018 Outlook Suggests Stability Amid OTC and Generic Industry Concerns
We don’t plan to alter our fair value estimate or no-moat rating for Perrigo as we make a few adjustments to our model. The company’s fourth-quarter results mostly matched our expectations, but management’s outlook for 2018 incorporates lower-than-expected growth in the domestic consumer health segment, offset by growth above our forecasts for the international consumer and prescription segments. New product launches in the prescription segment, including a potential generic launch of Teva’s Pro...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.